- Home
- ZEO vs EDSA Comparison
ZEO vs EDSA Comparison
Compare ZEO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- EDSA
- Stock Information
- Founded
- ZEO 2005
- EDSA 2015
- Country
- ZEO United States
- EDSA Canada
- Employees
- ZEO N/A
- EDSA N/A
- Industry
- ZEO
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- EDSA Health Care
- Exchange
- ZEO NYSE
- EDSA Nasdaq
- Market Cap
- ZEO 14.6M
- EDSA 13.8M
- IPO Year
- ZEO N/A
- EDSA N/A
- Fundamental
- Price
- ZEO $1.45
- EDSA $4.30
- Analyst Decision
- ZEO
- EDSA Strong Buy
- Analyst Count
- ZEO 0
- EDSA 2
- Target Price
- ZEO N/A
- EDSA $39.00
- AVG Volume (30 Days)
- ZEO 3.1M
- EDSA 13.5K
- Earning Date
- ZEO 11-20-2024
- EDSA 08-09-2024
- Dividend Yield
- ZEO N/A
- EDSA N/A
- EPS Growth
- ZEO N/A
- EDSA N/A
- EPS
- ZEO 0.67
- EDSA N/A
- Revenue
- ZEO $95,455,763.00
- EDSA N/A
- Revenue This Year
- ZEO N/A
- EDSA N/A
- Revenue Next Year
- ZEO N/A
- EDSA N/A
- P/E Ratio
- ZEO $2.42
- EDSA N/A
- Revenue Growth
- ZEO N/A
- EDSA N/A
- 52 Week Low
- ZEO $1.14
- EDSA $2.50
- 52 Week High
- ZEO $12.34
- EDSA $6.46
- Technical
- Relative Strength Index (RSI)
- ZEO 38.26
- EDSA 48.64
- Support Level
- ZEO $1.55
- EDSA $4.20
- Resistance Level
- ZEO $1.88
- EDSA $4.44
- Average True Range (ATR)
- ZEO 0.30
- EDSA 0.26
- MACD
- ZEO -0.02
- EDSA -0.02
- Stochastic Oscillator
- ZEO 1.39
- EDSA 30.00
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.